Covidien has finalized its purchase of CV Ingenuity for undisclosed terms. The company will integrate CV Ingenuity's business into its vascular product portfolio, the Covidien said in a statement.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||